# U.S. Senate Committee Pushes for Hemp Banking Reform in 2026
In a significant development for the hemp and CBD industry, a U.S. Senate committee held a hearing on April 9, 2026, to address long-standing banking challenges faced by hemp-related businesses. The Senate Committee on Banking, Housing, and Urban Affairs discussed proposed amendments to the SAFE Banking Act, aiming to provide clearer protections for financial institutions that serve hemp and cannabis companies. This move comes as the industry continues to grapple with restricted access to banking services due to federal uncertainty over cannabis-related regulations.
Why Banking Remains a Barrier
Despite the legalization of hemp under the 2018 Farm Bill, many banks and credit unions remain hesitant to work with hemp and CBD businesses. The primary concern stems from the overlap between hemp-derived products and marijuana, which remains a Schedule I controlled substance at the federal level. Financial institutions fear potential legal repercussions or loss of federal backing if they engage with businesses that might inadvertently cross regulatory lines. As a result, many hemp companies are forced to operate on a cash-only basis, increasing risks of theft and limiting their ability to scale.
The SAFE Banking Act, first introduced in 2019, seeks to shield banks from federal penalties when servicing state-legal cannabis and hemp businesses. While the bill has passed the House multiple times, it has repeatedly stalled in the Senate. The 2026 hearing signals renewed momentum, with senators from both parties acknowledging the economic potential of the hemp industry, which generated over $800 million in revenue in 2025, according to industry estimates.
Key Points from the Hearing
During the session, senators highlighted the need for explicit language in the SAFE Banking Act to cover hemp-derived products, including CBD and other cannabinoids. Committee Chair Senator Sherrod Brown (D-OH) emphasized that “hemp farmers and small businesses deserve the same financial tools as any other legal industry.” Witnesses, including representatives from the U.S. Hemp Roundtable, testified about the challenges of securing loans, credit card processing, and insurance without federal banking protections.
On the other side, some senators expressed concerns about potential loopholes that could allow illicit marijuana businesses to exploit banking reforms. Senator Mike Crapo (R-ID) called for stricter oversight mechanisms to ensure compliance with federal hemp regulations, particularly regarding THC content limits.
What This Means for the Industry
If the SAFE Banking Act amendments pass, they could unlock significant growth for the hemp and CBD sectors. Access to banking services would enable companies to invest in infrastructure, expand distribution networks, and compete on a larger scale. Small businesses, in particular, stand to benefit, as many currently struggle with high transaction costs and limited financial options.
However, the path forward remains uncertain. The bill must still navigate a full Senate vote and potential reconciliation with the House. Additionally, ongoing debates over broader cannabis legalization could delay or complicate hemp-specific reforms. Industry advocates are cautiously optimistic, noting that bipartisan support for hemp banking reform has grown in recent years.
Industry Reactions and Next Steps
Trade groups like the National Industrial Hemp Council (NIHC) praised the hearing as a “critical step toward economic equity for hemp businesses.” Meanwhile, CBD retailers and manufacturers are urging lawmakers to act swiftly, citing the competitive disadvantage they face compared to other agricultural sectors.
As the Senate refines the SAFE Banking Act, stakeholders will be watching closely for updates. A revised bill could be introduced as early as Q2 2026, potentially aligning with broader Farm Bill discussions. For now, the hemp industry remains hopeful that 2026 will mark a turning point in resolving one of its most persistent challenges.
The outcome of this legislative push could redefine the financial landscape for hemp and CBD companies, paving the way for greater stability and innovation in a rapidly evolving market.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.